

**IN THE CLAIMS:**

Please cancel claims 1-16 and 32, without prejudice, and amend claim 17 and 24-26 as follows. This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

- 1-16. Canceled.
17. (Currently Amended) An antibody which specifically binds to a polypeptide ~~according to claim 13 having at least 80% amino acid sequence identity to SEQ ID NO: 1.~~
18. (Original) The antibody of claim 17, wherein said antibody is a monoclonal antibody, a humanized antibody or a single-chain antibody.
19. (Original) The antibody of claim 17, wherein said antibody is a human antibody.
20. (Original) The antibody of claim 17, wherein said antibody is a murine antibody.
21. (Original) The antibody of claim 17, wherein the antibody comprises SEQ ID NO: 10.
22. (Original) The antibody of claim 17 wherein the antibody comprises SEQ ID NO: 12.
23. (Original) The antibody of claim 17 wherein the antibody comprises any of SEQ ID NOS: 13 through 33.
24. (Currently Amended) ~~Isolated~~ An isolated nucleic acid that encodes an antibody in accordance with claim 17.
25. (Currently Amended) ~~Isolated~~ The isolated nucleic acid ~~as in~~ of claim 24 wherein the isolated nucleic acid has at least 80% nucleic acid sequence identity to a nucleotide sequence shown of SEQ ID NO: 9.
26. (Currently Amended) ~~Isolated~~ The isolated nucleic acid ~~as in~~ of claim 24 wherein the isolated nucleic acid has at least 80% nucleic acid sequence identity to a nucleotide sequence shown of SEQ ID NO: 10.

27. (Original) A vector comprising the nucleic acid of claim 24.

28. (Original) A host cell comprising the vector of claim 27.

29. (Original) A process for producing an antibody comprising culturing the host cell of claim 28 under conditions suitable for expression of said antibody and recovering said antibody from the cell culture.

30. (Original) A method for identifying chronic lymphocytic leukemia cells, said method comprising contacting said cells with an anti-FLJ32028 antibody.

31. (Original) A method for detecting the presence of chronic lymphocytic leukemia cells in a mammal, said method comprising comparing the level of expression of FLJ32028 in (a) a test sample of cells taken from said mammal and (b) a control sample of normal cells of the same cell type, wherein a higher level of expression of said FLJ32028 in the test sample as compared to the control sample is indicative of the presence of chronic lymphocytic leukemia cells in said mammal.

32. (Canceled)

33. (Original) An antibody in accordance with claim 17 that comprises a variable light chain CDR1 region that comprises an amino acid sequence selected from the group consisting of QDISNY (SEQ ID NO: 34), KSLLYKDGKTY (SEQ ID NO: 35), QSLLYSSNQKNY (SEQ ID NO: 36) and QSIVHSNGNTY (SEQ ID NO: 37).

34. (Original) An antibody in accordance with claim 17 that comprises a variable heavy chain CDR1 region that comprises an amino acid sequence selected from the group consisting of GYTFTDYEMH (SEQ ID NO: 38), DYTFTDYEMH (SEQ ID NO: 39), GYTFTDYEVH (SEQ ID NO: 40), GFNIKDTYIN (SEQ ID NO: 41), GFTFSDYAMS (SEQ ID NO: 42), GFNFNTYAMN (SEQ ID NO: 43), GYTFTNSWIH (SEQ ID NO: 44), GFNIKDTYMN (SEQ ID NO: 45), GYTFTDYEMH (SEQ ID NO: 46), GFTFNTYAMN (SEQ ID NO: 47) and GYTFTDYEMH (SEQ ID NO: 48).

35. (Original) An antibody in accordance with claim 17 that comprises a variable light chain CDR2 region that comprises an amino acid sequence selected from the group consisting of YTS (SEQ ID NO: 49), FMS (SEQ ID NO: 50), WAS (SEQ ID NO: 51) and KVS (SEQ ID NO: 52).

36. (Original) An antibody in accordance with claim 17 that comprises a variable heavy chain CDR2 region that comprises an amino acid sequence selected from the group consisting of GIDPEIGGTVYNQKFKG (SEQ ID NO: 53), GIDPETGGTVYNQKLKG (SEQ ID NO: 54), GIDPESGGTAYNQKFKG (SEQ ID NO: 55), RIDPANNNTNYDPKFQG (SEQ ID NO: 56), MIDPANGNTQYDPKFQG (SEQ ID NO: 57), SISSGGTTYYLDSVKG (SEQ ID NO: 58), RIRTKSNNYATYYADSVKD (SEQ ID NO: 59), RIRSKSNNYATYYADSVKD (SEQ ID NO: 60), YIHPGPGYTEYNQNFKD (SEQ ID NO: 61), GIDPANDNTEYVPKFQG (SEQ ID NO: 62), GIDPETGGTVYNQKFKG (SEQ ID NO: 63), RIRTKSNNYATYYADSVKD (SEQ ID NO: 64) and GIDPETGGTVYNQKFKG (SEQ ID NO: 65).

37. (Original) An antibody in accordance with claim 17 that comprises a variable light chain CDR3 region that comprises an amino acid sequence selected from the group consisting of QQGNTLPFTFGSG (SEQ ID NO: 66), QQLVEYPLTFGAG (SEQ ID NO: 67), QQYYSYPLTFGAG (SEQ ID NO: 68), QQYYSYPLTIGAG (SEQ ID NO: 69) and FQGSHVPLTFGAG (SEQ ID NO: 70).

38. (Original) An antibody in accordance with claim 17 that comprises a variable heavy chain CDR3 region that comprises an amino acid sequence selected from the group consisting of FAY (SEQ ID NO: 71), GVY (SEQ ID NO: 72), GAD (SEQ ID NO: 73), GGYFDY (SEQ ID NO: 74), SETNY (SEQ ID NO: 75), HEGDWFA Y (SEQ ID NO: 76), HEGNWFA Y (SEQ ID NO: 77), GGDWGY (SEQ ID NO: 78), GGYFDY (SEQ ID NO: 79), WDY (SEQ ID NO: 80), QGENRFAY (SEQ ID NO: 81) and SLP (SEQ ID NO: 82).

39. (Original) An antibody comprising a heavy chain CDR1 region having the sequence GFTFNTYAMN (SEQ ID NO: 47).

40. (Original) An antibody comprising a heavy chain CDR2 region having the sequence RIRTKSNNYATYYADSVKD (SEQ ID NO: 59).

41. (Original) An antibody comprising a heavy chain CDR3 region having the sequence QGENRFAY (SEQ ID NO: 81).

42. (Original) An antibody comprising a heavy chain CDR1 region having the sequence GFTFNTYAMN (SEQ ID NO: 47), a heavy chain CDR2 region having the

sequence RIRTKSNNYATYYADSVKD (SEQ ID NO: 59) and a heavy chain CDR3 region having the sequence QGENRFAY (SEQ ID NO: 81).